Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 49, 2019 - Issue 5
174
Views
2
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Development of simultaneous quantification method of loteprednol etabonate (LE) and its acidic metabolites, and analysis of LE metabolism in rat

, , &
Pages 569-576 | Received 02 May 2018, Accepted 19 May 2018, Published online: 05 Jul 2018

References

  • Amon M, Busin M. (2012). Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol 32:507–17.
  • Bahar FG, Ohura K, Ogihara T, Imai T. (2012). Species difference of esterase expression and hydrolase activity in plasma. J Pharm Sci 101:3979–88.
  • Berry LM, Wollenberg L, Zhao Z. (2009). Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett 3:70–7.
  • Bodor N, Bodor N, Wu WM. (1992a). A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits. Curr Eye Res 11:525–30.
  • Bodor N, Buchwald P. (2000). Soft drug design: general principles and recent applications. Med Res Rev 20:58–101.
  • Bodor N, Buchwald P. (2002). Design and development of a soft corticosteroids, lotepredonol etabonate. In: Schleimer RP, O’Byrne PM, Szefler SJ, Brattsand R, eds. Inhaled steroid in asthma. Optimizing effects in the airways. New York, NY: Marcel Dekker, 541–64.
  • Bodor N, Buchwald P. (2004). Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites. Mol Biotechnol 26:123–32.
  • Bodor N, Buchwald P. (2005). Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 7:E820–33.
  • Bodor N, Buchwald P. (2006). Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 12:3241–60.
  • Bodor N, Loftsson T, Wu WM. (1992b). Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 9:1275–8.
  • Bodor N, Murakami T, Wu WM. (1995a). Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats–for safer treatment of gastrointestinal inflammation. Pharm Res 12:869–874.
  • Bodor N, Wu WM, Murakami T, Engel S. (1995). Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 12:875–9.
  • Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–54.
  • Buchwald P, Bodor N. (2004). Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity. Pharmazie 59:396–404.
  • Druzgala P, Hochhaus G, Bodor N. (1991a). Soft drugs 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol 38:149–54.
  • Druzgala P, Wu WM, Bodor N. (1991). Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 10:933–7.
  • Food and Drug Administration. (1997). International Conference on Harmonization (ICH), Q2b: Validation of Analytical Procedures: Methodology. 62 FR 27463. Federal Registry, 19 May 1997.
  • Howes JF. (2000). Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie 55:178–83.
  • Ilyas H, Slonim CB, Braswell GR, et al. (2004). Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 30:10–3.
  • Li B, Sedlacek M, Manoharan I, et al. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84.
  • Ohura K, Tasaka K, Hashimoto M, Imai T. (2014). Distinct patterns of aging effects on the expression and activity of carboxylesterases in rat liver and intestine. Drug Metab Dispos 42:264–73.
  • Samir A, Bodor N, Imai T. (2017). Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol 127:82–9.
  • Wu WM, Huang F, Lee Y, et al. (2008). Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats. J Pharm Pharmacol 60:291–7.
  • Wu WM, Tang Y, Buchwald P, Bodor N. (2010). Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. Pharmazie 65:412–6.
  • Yamaoka K, Nakagawa T. (1983). A nonlinear least squares program based on differential equations, MULTI (RUNGE), for microcomputers. J Pharmacobiodyn 6:595–606.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.